logo-loader
RNS
viewMaxCyte Inc

MaxCyte to Present at BIO-Europe 2019

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:16.0pt;margin-left:0cm;text-align:center;font-size:14.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h2{margin-top:0cm;margin-right:0cm;margin-bottom:48.0pt;margin-left:0cm;text-align:center;font-size:14.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:16.0pt;margin-left:0cm;text-align:center;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h4{margin:0cm;margin-bottom:.0001pt;text-align:center;line-height:12.0pt;border:none;padding:0cm;font-size:9.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h5{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;text-align:justify;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h6{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;text-align:justify;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight:normal;font-div:italic;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #000000 } visited{ color: purple } .fx{size:612.0pt 792.0pt;margin:40.5pt 72.0pt 36.0pt 72.0pt;}div.fx{}p.hk{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 115%; margin-right: .2pt; text-align: center}span.hi{line-height:115%;font-family:"Calibri","sans-serif"}span.hg{font-size:14.0pt;line-height:115%; font-family:"Calibri","sans-serif"}span.hf{font-size:14.0pt;line-height:115%; font-family:"Calibri","sans-serif";color:black}p.hl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:.2pt;text-align:justify;line-height: 115%;text-autospace:none}span.hd{font-size:11.0pt; line-height:115%;font-family:"Calibri","sans-serif"}span.he{color:black}span.hc{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"} span.ha{font-size:11.0pt;line-height: 115%;font-family:"Calibri","sans-serif"}span.gz{font-size:11.0pt;line-height: 115%;font-family:"Calibri","sans-serif";color:black}p.hm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 115%; margin-right: .2pt; text-align: justify}span.gy{font-size:11.0pt;line-height:115%;font-family: "Calibri","sans-serif"}p.hn{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 115%; margin-right: .2pt}p.ho{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:.2pt;text-align:justify;line-height: 115%}span.gv{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"; color:black}span.gu{font-size: 11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}p.hp{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 150%; margin-right: .2pt; text-autospace: none}span.gs{font-size:11.0pt;line-height:150%;font-family: "Calibri","sans-serif";color:black} p.hq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:.2pt;line-height:150%;text-autospace: none}p.hr{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: .2pt; text-autospace: none}span.gp{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}table.hs{width:456.3pt;border-collapse:collapse}tr.gi{height:14.05pt}td.gk{width:242.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:14.05pt}p.ht{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: .2pt}span.gn{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.hu{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:.2pt}td.gj{width:191.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:14.05pt} tr.gd{height:79.55pt}td.gf{width:242.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:79.55pt}p.hv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; font-weight: bold; margin-right: .2pt}span.gh{font-size: 11.0pt;font-family:"Calibri","sans-serif"}td.ge{width:191.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:79.55pt}p.fz{font-weight: bold}span.ga{font-size:12.0pt;font-family:"Times New Roman","serif"}br.gb{page-break-before:auto}.fy{size:612.0pt 792.0pt;margin:45.0pt 72.0pt 36.0pt 72.0pt;}div.fy{} p.bh,li.bh,div.bh{margin-top:0cm;margin-right:0cm;margin-bottom:12.0pt;margin-left:0cm;text-align:justify;font-size:12.0pt;font-family:"Times New Roman","serif";} /**/
RNS Number : 5671S
MaxCyte, Inc.
07 November 2019
 

 

 

 

MaxCyte to Present at BIO-Europe 2019 

 

Gaithersburg, Maryland - 07 November 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company, announces that President and Chief Executive Officer Doug Doerfler will present on the Company's CARMA™ cell-therapy platform at the annual BIO Europe conference on 13 November 2019 at Hamburg Messe, Hamburg, Germany.

 

The presentation, which will take place at 10:30 a.m. CET in Hall B1, Room 6, will focus on MaxCyte's position at the forefront of the development of next generation cell-based medicines with the proprietary CARMA platform.

 

CARMA is MaxCyte's clinical-stage, non-viral, mRNA-based cell therapy platform that allows for the transfection of mRNA into cells and provides a simple, rapid-to-manufacture, dose-controllable product. CARMA requires less than one day for manufacture therapies for patients, where existing CAR-T therapies require one to two weeks or more to manufacture. MaxCyte's wholly-owned lead CARMA candidate, MCY-M11, is currently being evaluated in a Phase I clinical trial in patients with advanced ovarian cancer and peritoneal mesothelioma.

 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including six announced commercial licenses with aggregate potential milestones of more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

 

For further information, please contact:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

 

+1 301 944 1660

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

 

+44 (0)203 709 5700

[email protected]


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRABFBJTMBTMTIL

Quick facts: MaxCyte Inc

Price: 117.3

Market: AIM
Market Cap: £67.32 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18